Andrew Lacey
Managing Principal
Australian Competition and Consumer Commission v Pfizer Australia Pty Ltd [2015] FCA 113
In what has turned out to be another unsuccessful attempt by the ACCC to prosecute a misuse of market power case, the Federal Court of Australia, in Australian Competition and Consumer Commission v Pfizer Australia Pty Ltd [2015] FCA 113, has dismissed the ACCC’s allegations that Pfizer Australia Pty Ltd (Pfizer) breached the Competition and Consumer Act 2010 (CCA) by engaging in misuse of market power and exclusive dealing regarding its commercial strategy in the lead up to the expiration of its Lipitor patent.
Atorvastatin is a medication that blocks the production of cholesterol. Until 18 May 2012, Pfizer held the patent over the atorvastatin molecule. Pfizer marketed and sold atorvastatin under the brand name ‘Lipitor’. Between 2010 and 2013, atorvastatin was the highest selling prescription pharmaceutical in Australia with sales exceeding $700 million a year for the financial years ending June 2010, June 2011 and June 2012.
Not surprisingly, the expiration of Pfizer’s patent was highly anticipated by generic drug manufacturers wanting to sell their own atorvastatin products as soon as they could lawfully do so.
In anticipation of this increased competition, Pfizer implemented a number of sales and marketing changes. These included:
The ACCC claimed that the above course of conduct contravened the CCA. It alleged that:
Pfizer disputed all of the allegations.
The Court held that the ACCC’s misuse of market power claim was pleaded in such a ‘legally incoherent’ manner that it could have been summarily dismissed. However, the Court chose not to do so, instead finding that the allegations failed for the following reasons:
Pfizer conceded that the condition placed on pharmacies requiring them to not exceed sales of more than 25% of competitor’s generic atorvastatin fell within the definition of exclusive dealing. However, Pfizer disputed the ACCC’s claim that the conduct was undertaken for the purpose of substantially lessening competition. The Court agreed and concluded that the claim failed for the following reasons:
The ACCC failed to establish both the misuse of market power and exclusive dealing claims and was ordered to pay Pfizer’s costs in the proceedings.
This case supports the proposition that the conduct of a corporation for the purpose of remaining competitive in a market following the expiry of its patent, will not, in itself, amount to anti-competitive conduct. This case also highlights the importance of pleading your case in a structured and logical manner.
The case has also highlighted the subjective nature of the purpose test used when assessing misuse of market power. The Court found that although Pfizer’s purpose was not anti-competitive, the likely effect of its conduct was. In its submissions to the Harper Review, the ACCC has called for the misuse of market power test to include a ‘likely effects’ test.
For a full copy of the judgment please click here.
For further information or assistance with your own intellectual property or competition and consumer law matters please contact Jimmy Gill.
This article is not legal advice. It is intended to provide commentary and general information only. Access to this article does not entitle you to rely on it as legal advice. You should obtain formal legal advice specific to your own situation. Please contact us if you require advice on matters covered by this article.